Skip to content
AnalystLens

BOSTON SCIENTIFIC CORP 8-K Report, Financial Results (Apr 22, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed April 22, 2026
Period End
April 22, 2026
Security
BSX
In the record · 2016–202610-K1310-Q328-K181

BSX filed 13 annual reports (10-K), 32 quarterly reports (10-Q) and 181 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Feb ’17Feb ’17
  2. Material agreement8-K · Feb ’19Feb ’19
  3. Leadership change8-K · Aug ’21Aug ’21
  4. Leadership change8-K · Apr ’25Apr ’25

01—Abstract

Summary

Summary of the 8-K filed April 22, 2026. Cited figures are marked; the original filing is the authoritative source.

Boston Scientific (BSX) reported first-quarter 2026 net sales of $5.203 billiona, up 11.6% on a reported basis and 9.4% on an operational and organic basis, both above the company's guidance ranges of 10.5–12.0% reported and 8.5–10.0% organic.

Growth was led by Cardiovascular (up 11.2% organic, with the WATCHMAN and FARAPULSE franchises cited in clinical and regulatory updates) and Neuromodulation (up 15.4% organic within MedSurg). Results were weaker in EMEA, which grew only 1.2% operationally, while the U.S. grew 10.9% and APAC and LACA grew 12.0% each. GAAP net income attributable to common stockholders was $1.341 billionb, or $0.90 per diluted share, versus $0.45 a year earlier.

The GAAP figure was inflated by a large deferred tax benefit of $320 millionc (about $0.21 per share) and investment portfolio gains of $137 million pre-tax, so it should not be read as a clean run-rate. Adjusted EPS was $0.80, above the $0.78–$0.80 guidance range and up from $0.75 in the prior year period. Management raised full-year 2026 guidance to 7.0–8.5% reported and 6.5–8.0% organic net sales growth, with adjusted EPS of $3.34–$3.41.

Second-quarter guidance calls for 5.5–7.5% reported and 5.0–7.0% organic growth, with adjusted EPS of $0.82d–$0.84. The filing also disclosed completion of the Valencia Technologies acquisition, U.S. FDA 510(k) clearance of the Asurys Fluid Management System, and two new board members.

02—Key points

Key Highlights

  1. Q1 2026 net sales of $5.203B grew 11.6% reported and 9.4% organic, beating the company's own guidance ranges on both measures.
  2. Cardiovascular sales rose 13.5% reported (11.2% organic) to $3.503B, while MedSurg rose 7.8% reported (5.7% organic) to $1.701B, with Neuromodulation the fastest-growing unit at 15.4% organic.
  3. Adjusted EPS of $0.80 topped the $0.78–$0.80 guidance range and rose from $0.75 a year earlier; GAAP diluted EPS of $0.90 was boosted by a $320M deferred tax benefit and $137M of investment gains.
  4. Full-year 2026 guidance was raised to 6.5–8.0% organic growth and $3.34–$3.41 adjusted EPS; Q2 guidance calls for 5.0–7.0% organic growth and $0.82–$0.84 adjusted EPS.
  5. EMEA is a clear weak spot, with operational growth of only 1.2% versus 12.0% in APAC and LACA and 10.9% in the U.S.
  6. Operating income rose to $1.101B from $921M, and gross margin improved to roughly 69.5% from 68.8% a year earlier (computed from reported gross profit of $3.614B on $5.203B net sales).
  7. Clinical and regulatory momentum included CHAMPION-AF results for WATCHMAN FLX published in NEJM, HI-PEITHO results for EKOS, ADVENT four-year outcomes for FARAPULSE, and China approval of the OPAL HDx mapping system.

03—Questions

Frequently Asked Questions

  1. Did Boston Scientific beat its Q1 2026 guidance?

    Yes. Reported net sales growth of 11.6% exceeded the 10.5–12.0% guidance range, organic growth of 9.4% exceeded the 8.5–10.0% range, and adjusted EPS of $0.80 landed at the top of the $0.78–$0.80 range.

  2. Why is GAAP EPS of $0.90 so much higher than adjusted EPS of $0.80?

    Adjusted EPS removes items that lowered GAAP earnings, such as $0.14 of amortization, and includes the GAAP results after the company's exclusions. GAAP EPS is higher here because it includes a $320M deferred tax benefit (about $0.21 per share) and $137M of pre-tax investment portfolio gains, which are excluded from adjusted EPS. Investors should treat the one-time benefits as non-recurring.

  3. How did guidance change for 2026?

    Full-year organic net sales growth guidance is 6.5–8.0% and reported growth is 7.0–8.5%, with adjusted EPS of $3.34–$3.41. The filing describes these as updated estimates; the prior guidance values are not included in this filing, so the size of the change cannot be measured from it. Second-quarter guidance is 5.0–7.0% organic growth and $0.82–$0.84 adjusted EPS.

  4. Which segments and regions drove growth, and where was it weakest?

    Cardiovascular (+11.2% organic) and Neuromodulation (+15.4% organic) led growth, and APAC and LACA each grew 12.0% operationally, with the U.S. at 10.9%. EMEA was the weak spot at only 1.2% operational growth, and Urology grew just 0.5% organically.

  5. Were there any notable acquisitions or regulatory milestones?

    Boston Scientific completed its acquisition of Valencia Technologies, which develops the eCoin implantable tibial nerve stimulation system for urge urinary incontinence. The company also received FDA 510(k) clearance for the Asurys Fluid Management System and China NMPA approval for the OPAL HDx Mapping System, and it announced clinical results including CHAMPION-AF, HI-PEITHO, and ADVENT long-term outcomes.

04—Continue

← View all 8-K filings